Vitality Watch

Dossier pubmed review 11-jun-2026
Narrative review or expert overview without new data

Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine.

Key claim: A review argues that regenerative therapies, targeted anti-inflammatory agents, and senolytic or senomorphic approaches can move osteoarthritis beyond NSAIDs and corticosteroids toward disease-modifying, phenotype-aligned precision interventions.

Abstract

Osteoarthritis (OA) is a prevalent chronic degenerative joint disease that significantly impacts the quality of life for over 500 million individuals affected. OA is increasingly recognized as a whole-joint disorder characterized by complex biochemical and cellular changes across various joint tissues. However, traditional approaches such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids often fall short in halting disease progression or restoring joint function. Thereby, recent innovations in OA management are focused on underlying pathophysiology, driving the development of regenerative therapies, targeted anti-inflammatory agents and senolytic or senomorphic approaches. Accordingly, this paper reviews current progress in these areas by integrating evidence from clinical and pre-clinical studies to clarify therapeutic limitations, unresolved mechanistic and phenotypic gaps and the emerging strategies required to advance disease-modifying therapy in OA. It further outlines pathways toward precision, phenotype-aligned interventions, an integration that current literature has not yet consolidated.

Why this matters

A review argues that regenerative therapies, targeted anti-inflammatory agents, and senolytic or senomorphic approaches can move osteoarthritis beyond NSAIDs and corticosteroids toward disease-modifying, phenotype-aligned precision interventions.

Source

Link

Briefing card

Novel therapeutic strategies for osteoarthritis: from mechanistic insights to precision medicine.
Stage: review · pubmed · 11-jun-2026

A review argues that regenerative therapies, targeted anti-inflammatory agents, and senolytic or senomorphic approaches can move osteoarthritis beyond NSAIDs and corticosteroids toward disease-modifying, phenotype-aligned precision interventions.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1038/s41413-026-00540-6

build build 880 · 2bcef25 · 2026-11-18